Commentary: "Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression"


Published in:
Frontiers in Psychiatry

DOI:
10.3389/fpsyt.2015.00117

Link to publication

Creative Commons License (see https://creativecommons.org/use-remix/cc-licenses):
CC BY

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
Commentary: “Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression”

Eiko I. Fried1*, Lynn Boschloo2, Claudia D. van Borkulo2,3, Robert A. Schoevers2, Jan-Willem Romeijn4, Marieke Wichers2,5, Peter de Jonge2, Randolph M. Nesse6, Francis Tuerlinckx1 and Denny Borsboom3

1 Faculty of Psychology, University of Leuven, Leuven, Belgium. 2 Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 3 Department of Psychology, University of Amsterdam, Amsterdam, Netherlands. 4 Faculty of Philosophy, University of Groningen, Groningen, Netherlands. 5 Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands. 6 School of Life Sciences, Arizona State University, Tempe, AZ, USA

Keywords: selective serotonin reuptake inhibitors, major depressive disorder, network analysis, antidepressants, symptomics

A commentary on

Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression


In the past decades, almost all research in psychiatry and clinical psychology has been directed at the level of disorders, such as major depressive disorder (MDD) or schizophrenia. As has been argued by many scholars in recent work, this organization of the psychiatric research program has yielded limited insights, which justifies the investigation of psychopathology at a more fine-grained level: the level of symptoms (1, 2). In the present letter, we indicate two primary directions for this research program, which we propose to call symptomics. We will focus our discussion on MDD specifically and discuss possibilities in relation to the recently published work by Hieronymus et al. (3).

Firstly, research has now shown that distinct depression symptoms, such as sad mood or insomnia differ in the risk factors that predispose them (4, 5), their underlying biology (6, 7), their response to specific life events (8, 9), and their impact on impairment of psychosocial functioning (10, 11) [for a review, see Ref. (1)]. This presents the first direction of the research agenda: to further investigate the properties in which individual symptoms differ from each other. The recently published work by Hieronymus et al. (3), “Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression”, adds the differential reactivity of depression symptoms to antidepressant medication to the prior body of work. In their analysis of clinical trial data of 6,669 patients with MDD published in Molecular Psychiatry, the authors document that depressive symptoms responded differentially to treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants. Pooled effect sizes ranged from 0 (for symptoms, such as gastrointestinal and genital symptoms) to 0.44 (for depressed mood, a core symptom of depression). Hieronymus et al. (3) argue that these findings are consistent with prior antidepressant research that found differential treatment effects on symptoms and stress the importance of analyzing individual depression symptoms in future studies. We would like to extend their claim: these results, along with previous symptom-based findings, mandate the examination of symptom-specific effects throughout the realm of psychopathology.
The second research direction is the investigation of distinct patterns of causes and effects in which symptoms operate. Network analysis provides a tool to investigate these specific associations between symptoms that can sustain mental disorders (2). Contrasting the traditional explanation that the co-occurrence of symptoms (such as the depressive syndrome) is due to one underlying shared origin (MDD causes depression symptoms), networks conceptualize depression as a complex dynamic system of mutually reinforcing associations (12, 13). Figure 1 presents an example of such a psychopathological network – in the form of a Markov random field (MRF) – for the Hamilton Depression Rating Scale (HRSD), the same instrument analyzed by Hieronymus et al. (3). We computed the network from the enrollment symptom data of 3,467 patients from the antidepressant trial “sequenced treatment alternatives to relieve depression” (STAR*D) (14), a dataset that can be requested at the NIMH. The network can be viewed as a tentative estimate of the causal skeleton of a disorder and may be used to gauge which symptoms are most central in receiving input, and/or sending out influences into the system (15). Applying a network perspective to the paper by Hieronymus et al. (3) gains considerable analytic power. For example, the centrality of the STAR*D HRSD symptoms, as measured by their closeness to other symptoms in the network (2), correlates $r = 0.53$ ($p < 0.05$) with the symptom effect sizes reported by the authors. This means that more central symptoms exhibit greater reactivity to the intervention. In addition, symptoms with a higher closeness have a higher reported baseline severity ($r = 0.60$, $p < 0.05$) and symptoms with a higher baseline severity exhibit a (much) larger effect size ($r = 0.77$, $p < 0.001$). Thus, an interesting three-way pattern arises with more central HRSD items exhibiting higher reported means and higher reported reactivity to interventions.

While we can only speculate as to what produces this intriguing pattern of effects, the most important message is that focusing on the level of symptoms and analyzing the causal relations among them is likely to extend our understanding of psychopathology directly and significantly. The widespread reliance on disorders and the associated focus on symptom sum-scores in investigations of the biology and treatment of psychopathology may have concealed crucial insights (1, 16). A number of multivariate approaches have been developed for, and used with, depression symptoms previously, including structural equation models and network analyses (4, 9); in addition, time-series analysis studying network dynamics has become available as a tool to zoom in on the micro-level interactions among symptoms (17). Paying close attention to symptoms and their dynamics may have important clinical implications. Due to the highly heterogeneous nature of MDD (18, 19), individuals may differ substantially from each other not only in the symptoms they exhibit, but also in the way their symptoms are related to contextual influences, and in the way symptoms shape each other across time. A treatment focus on especially prevalent and central symptoms, instead of the categorically defined and heterogeneous disorders itself, may help increase the currently disappointing levels of treatment response (20). A broader investigation of symptom-specific treatment effects similar to the study performed by Hieronymus et al. (3) would enable clinical trials to match participants to specific treatments, based on their symptom profiles and dynamics.

In summary, symptomics invites the application of new modeling efforts to the level of individual symptoms as fundamental building blocks of mental disorders. As such, it may herald a time of renewed research energy that could, finally, provide an inroad to achieve real understanding of the mechanisms underlying psychopathology.

**Acknowledgments**

The STAR*D study was supported by NIMH Contract #N01MH90003 to the University of Texas Southwestern Medical Center (http://www.nimh.nih.gov). The ClinicalTrials.gov identifier is NCT00021528. This manuscript reflects the views of the authors and may not reflect the opinions or views of the STAR*D study investigators or the NIMH.
References


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Fried, Boshloo, van Borkulo, Schoevers, Romeijn, Wichers, de Jonge, Nesse, Tuerlinckx and Borsboom. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.